CervoMed (CRVO) Income from Continuing Operations (2010 - 2026)
CervoMed (CRVO) posted Income from Continuing Operations of 8116876.0 for Q1 2026, little changed sequentially from 8090581.0 in Q4 2025, and down 52.04% YoY from 16924242.72 in Q1 2025.
CervoMed (CRVO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
CervoMed has reported Income from Continuing Operations for 17 years, with the latest figure at 8116876.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 52.04% year-over-year to 8116876.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30576685.0 (down 49.61% YoY) and the FY2025 annual result came in at 26958040.0, down 48.34% from the prior year.
- Income from Continuing Operations steadied at 8116876.0 in Q1 2026 per CRVO's latest filing, from 8090581.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1248928.0 in Q2 2023 and troughed at 8116876.0 in Q1 2026.
- A 5-year average of 4552749.06 and a median of 4369412.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 77.06% in 2022, then sank 179.1% in 2024.
- Over 5 years, Income from Continuing Operations stood at 4075964.0 in 2022, then jumped by 35.74% to 2619360.0 in 2023, then tumbled by 179.1% to 7310570.0 in 2024, then retreated by 10.67% to 8090581.0 in 2025, then fell by 0.33% to 8116876.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 8116876.0, 8090581.0, and 7725838.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | -6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.57 Mn |
| Mar 31, 2026 | -8.12 Mn |
| Dec 31, 2025 | -8.09 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | -6.64 Mn |
| Mar 31, 2025 | -5.34 Mn |
| Dec 31, 2024 | -7.31 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -3.04 Mn |
| Mar 31, 2024 | -2.59 Mn |
| Dec 31, 2023 | -2.62 Mn |
| Sep 30, 2023 | -2.63 Mn |
| Jun 30, 2023 | -1.25 Mn |
| Mar 31, 2023 | -1.39 Mn |
| Dec 31, 2022 | -4.08 Mn |
| Sep 30, 2022 | -2.80 Mn |
| Jun 30, 2022 | -4.37 Mn |
| Mar 31, 2022 | -4.65 Mn |
| Dec 31, 2021 | -3.07 Mn |
| Sep 30, 2021 | -12.20 Mn |